# Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Canonical URL: https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2026-financial-results-and-highlights-recent-progress
Ticker: RCKT
Company: Rocket Pharmaceuticals
Source: Rocket Pharmaceuticals
Published: 2026-05-07 20:00 EST
Original Source URL: https://ir.rocketpharma.com
## Summary

Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 KRESLADI™ granted FDA accelerated approval; Rare Pediatric Disease Priority Review Voucher

## Article Body
Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 KRESLADI™ granted FDA accelerated approval; Rare Pediatric Disease Priority Review Voucher
## Recent Company News
- 2026-05-07 20:00 EST — [Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2026-financial-results-and-highlights-recent-progress) — Source: Rocket Pharmaceuticals
- 2026-04-28 11:00 EST — [Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-180-million-sale-of-priority-review-voucher) — Source: Rocket Pharmaceuticals
- 2026-03-27 11:00 EST — [Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-fda-approval-of-kresladitm-for-pediatric-patients-with-severe-leukocyte-adhesion-deficiency-i-lad-i) — Source: Rocket Pharmaceuticals
- 2026-02-26 21:00 EST — [Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-progress) — Source: Rocket Pharmaceuticals
- 2026-02-23 12:00 EST — [Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-to-participate-in-upcoming-investor-conferences) — Source: Rocket Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)